November 04, 2026
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026May 21, 2026
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in OncologyApril 28, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celFebruary 23, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel